Loading
A phase 2 trial of ARX788 in HER2-positive breast cancer, run by Ambrx, Inc., active and no longer recruiting.
ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03) is a phase 2 interventional study registered as NCT04829604 by Ambrx, Inc., with 72 participants enrolled, started 2021-10-26 and due to reach its primary completion in 2026-12. Interventions recorded: ARX788.
Shares Ambrx, ARX788, Site-specific conjugation & linker chemistry, HER2-positive breast cancer.
Shares HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tag pipeline.